Neurosciences became the stepchild of the pharma industry after a series of ugly setbacks in the clinic drove away the major players. But now, considering the advances in genetics and some new work on old ideas, some of the biggest outfits are driving a comeback of sorts as they team up or buy out some of the upstarts in this space. Endpoints examines the trend, and where it appears we’re headed now.